Please Wait.....
Report
Asia-Pacific Pemphigus Vulgaris Market
Market Report I 2025-06-01 I 350 Pages I Data Bridge Market Research
The Asia-pacific pemphigus vulgaris market is expected to reach USD 140.96 million by 2032 from USD 67.44 million in 2024, growing at a CAGR of 9.8% in the forecast period of 2025 to 2032.
Market Segmentation:
Asia-Pacific Pemphigus Vulgaris Market Segmentation, By Diagnosis and Treatment (Diagnosis and Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy), Countries (China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, New Zealand, Taiwan, Hong Kong, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2032
Overview of Asia-Pacific Pemphigus Vulgaris Market Dynamics:
Driver
- Emerging treatment options for pemphigus vulgaris
Restraint
- Stringent regulatory guidelines for pemphigus vulgaris drug approval
Opportunity
- Increasing demand for personalized medicine
Market Players:
The key market players operating in the Asia-pacific pemphigus vulgaris market are listed below:
- Merck & Co., Inc. (U.S.)
- Sanofi (France)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- AstraZeneca (U.K.)
- GRIFOLS SA (Spain)
- Zydus Group (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- GSK plc. (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- Celltrion (South Korea)
- Lilly (U.S.)
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Fresenius Kabi AG (Germany)
- Rakshit Drugs Private Limited (India)
- Amgen Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- CSL (Australia)
- Baxter (U.S.)
- Accord Healthcare (U.K.)
- DAEWOONG PHARMACEUTICAL CO., LTD. (South Korea)
- SUNPHARMA.NS (India)
- Cipla Health Ltd (India)
TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW 21
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.8 DBMR MARKET POSITION GRID 35
2.9 MARKET END USER COVERAGE GRID 36
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 45
4.1 PESTAL ANALYSIS 46
4.2 PORTERS FIVE FORCES ANALYSIS 47
4.3 PATENT ANALYSIS 48
4.3.1 PATIENT FLOW DIAGRAM 49
4.3.2 KEY PRICING STRATEGIES 50
4.3.3 FUTURE THERAPIES 50
4.3.4 KEY PATIENT ENROLLMENT STRATEGIES 51
4.4 ASIA-PACIFIC CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET 53
4.5 SUPPLY CHAIN ECOSYSTEM 59
4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET 61
4.7 EPIDEMIOLOGY: ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET 64
4.7.1 INCIDENCE BY GENDER 64
4.7.2 TREATMENT RATE 64
4.7.3 MORTALITY RATE 64
4.7.4 PATIENT TREATMENT SUCCESS RATES 65
5 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: REGULATIONS 66
6 MARKET OVERVIEW 72
6.1 DRIVERS 74
6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 74
6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS 75
6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS 76
6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS 77
6.2 RESTRAINTS 78
6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL 78
6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES 79
6.3 OPPORTUNITIES 80
6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 80
6.3.2 INCREASING HEALTHCARE FACILITIES 81
6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT 82
6.4 CHALLENGES 83
6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS 83
6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES 84
7 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 85
7.1 OVERVIEW 86
7.2 TREATMENT 89
7.3 DIAGNOSIS 91
8 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 92
8.1 OVERVIEW 93
8.2 ADULTS 96
8.3 GERIATRIC 96
8.4 PEDIATRIC 97
9 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER 98
9.1 OVERVIEW 99
9.2 HOSPITALS 102
9.3 SPECIALTY CLINICS 102
9.4 RESEARCH INSTITUTES 103
9.5 OTHERS 103
10 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 104
10.1 OVERVIEW 105
10.2 HOSPITALS PHARMACY 108
10.3 RETAIL PHARMACY 108
10.4 ONLINE PHARMACY 109
11 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY REGION 110
11.1 ASIA-PACIFIC 112
11.1.1 CHINA 116
11.1.2 INDIA 119
11.1.3 SOUTH KOREA 122
11.1.4 MALAYSIA 125
11.1.5 JAPAN 128
11.1.6 AUSTRALIA 131
11.1.7 SINGAPORE 134
11.1.8 THAILAND 137
11.1.9 INDONESIA 140
11.1.10 NEW ZEALAND 143
11.1.11 TAIWAN 146
11.1.12 PHILIPPINES 149
11.1.13 HONG KONG 152
11.1.14 REST OF ASIA-PACIFIC 155
12 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 156
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS 157
14 COMPANY PROFILE 158
14.1 MERCK AND CO. INC. 158
14.1.1 COMPANY SNAPSHOT 158
14.1.2 REVENUE ANALYSIS 158
14.1.3 COMPANY SHARE ANALYSIS 159
14.1.4 PRODUCT PORTFOLIO 159
14.1.5 RECENT DEVELOPMENTS 160
14.2 SANOFI 161
14.2.1 COMPANY SNAPSHOT 161
14.2.2 REVENUE ANALYSIS 161
14.2.3 COMPANY SHARE ANALYSIS 162
14.2.4 PRODUCT PORTFOLIO 162
14.2.5 RECENT DEVELOPMENT 163
14.3 REGENERON PHARMACEUTICALS INC. 164
14.3.1 COMPANY SNAPSHOT 164
14.3.2 REVENUE ANALYSIS 164
14.3.3 COMPANY SHARE ANALYSIS 165
14.3.4 PRODUCT PORTFOLIO 165
14.3.5 RECENT DEVELOPMENTS 166
14.4 JOHNSON & JOHNSON SERVICES, INC. 167
14.4.1 COMPANY SNAPSHOT 167
14.4.2 REVENUE ANALYSIS 167
14.4.3 COMPANY SHARE ANALYSIS 168
14.4.4 PRODUCT PORTFOLIO 168
14.4.5 RECENT DEVELOPMENT 169
14.5 ASTRAZENECA 170
14.5.1 COMPANY SNAPSHOT 170
14.5.2 REVENUE ANALYSIS 170
14.5.3 COMPANY SHARE ANALYSIS 171
14.5.4 PRODUCT PORTFOLIO 171
14.5.5 RECENT DEVELOPMENT 172
14.6 ABBVIE INC. 173
14.6.1 COMPANY SNAPSHOT 173
14.6.2 REVENUE ANALYSIS 173
14.6.3 PRODUCT PORTFOLIO 174
14.6.4 RECENT DEVELOPMENT 175
14.7 ACCORD HEALTHCARE 177
14.7.1 COMPANY SNAPSHOT 177
14.7.2 PRODUCT PORTFOLIO 177
14.7.3 RECENT DEVELOPMENT 177
14.8 AMGEN INC. 178
14.8.1 COMPANY SNAPSHOT 178
14.8.2 REVENUE ANALYSIS 178
14.8.3 PRODUCT PORTFOLIO 179
14.8.4 RECENT DEVELOPMENT 180
14.9 ARTIVA BIOTHERAPEUTICS, INC. 181
14.9.1 COMPANY SNAPSHOT 181
14.9.2 REVENUE ANALYSIS 181
14.9.3 PRODUCT PIPELINE PORTFOLIO 182
14.9.4 RECENT DEVELOPMENT 182
14.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 183
14.10.1 COMPANY SNAPSHOT 183
14.10.2 PRODUCT PORTFOLIO 183
14.10.3 RECENT DEVELOPMENT 183
14.11 BAXTER 184
14.11.1 COMPANY SNAPSHOT 184
14.11.2 REVENUE ANALYSIS 184
14.11.3 PRODUCT PORTFOLIO 185
14.11.4 RECENT DEVELOPMENT 185
14.12 BIOXPRESS THERAPEUTICS SA 186
14.12.1 COMPANY SNAPSHOT 186
14.12.2 PRODUCT PORTFOLIO 186
14.12.3 RECENT DEVELOPMENT 186
14.13 CABALETTA BIO INC. 187
14.13.1 COMPANY SNAPSHOT 187
14.13.2 REVENUE ANALYSIS 187
14.13.3 PRODUCT PORTFOLIO 187
14.13.4 RECENT DEVELOPMENT 188
14.14 CIPLA HEALTH LTD 189
14.14.1 COMPANY SNAPSHOT 189
14.14.2 PRODUCT PORTFOLIO 189
14.14.3 RECENT DEVELOPMENTS 189
14.15 CELLTRION 190
14.15.1 COMPANY SNAPSHOT 190
14.15.2 REVENUE ANALYSIS 190
14.15.3 PRODUCT PORTFOLIO 191
14.15.4 RECENT DEVELOPMENTS 192
14.16 CSL 193
14.16.1 COMPANY SNAPSHOT 193
14.16.2 REVENUE ANALYSIS 193
14.16.3 PRODUCT PORTFOLIO 194
14.16.4 RECENT DEVELOPMENT 194
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD. 195
14.17.1 COMPANY SNAPSHOT 195
14.17.2 REVENUE ANALYSIS 195
14.17.3 PRODUCT PORTFOLIO 196
14.17.4 RECENT DEVELOPMENT 196
14.18 F. HOFFMANN- LA ROCHE LTD. 197
14.18.1 COMPANY SNAPSHOT 197
14.18.2 REVENUE ANALYSIS 197
14.18.3 PRODUCT PORTFOLIO 198
14.18.4 RECENT DEVELOPMENT/NEWS 198
14.19 FRESENIUS KABI AG 200
14.19.1 COMPANY SNAPSHOT 200
14.19.2 REVENUE ANALYSIS 200
14.19.3 PRODUCT PORTFOLIO 201
14.19.4 RECENT DEVELOPMENT 201
14.20 GSK PLC 203
14.20.1 COMPANY SNAPSHOT 203
14.20.2 REVENUE ANALYSIS 203
14.20.3 PRODUCT PORTFOLIO 204
14.20.4 RECENT DEVELOPMENT 204
14.21 GRIFOLS, S.A. 206
14.21.1 COMPANY SNAPSHOT 206
14.21.2 REVENUE ANALYSIS 206
14.21.3 PRODUCT PORTFOLIO 207
14.21.4 RECENT DEVELOPMENT 207
14.22 INCYTE 208
14.22.1 COMPANY SNAPSHOT 208
14.22.2 REVENUE ANALYSIS 208
14.22.3 PRODUCT PORTFOLIO 209
14.22.4 RECENT DEVELOPMENT 209
14.23 NOVARTIS AG 210
14.23.1 COMPANY SNAPSHOT 210
14.23.2 REVENUE ANALYSIS 210
14.23.3 PRODUCT PORTFOLIO 211
14.23.4 RECENT DEVELOPMENT 211
14.24 LILLY 212
14.24.1 COMPANY SNAPSHOT 212
14.24.2 REVENUE ANALYSIS 212
14.24.3 PRODUCT PORTFOLIO 213
14.24.4 RECENT DEVELOPMENT 213
14.25 OCTAPHARMA AG 214
14.25.1 COMPANY SNAPSHOT 214
14.25.2 REVENUE ANALYSIS 214
14.25.3 PRODUCT PORTFOLIO 215
14.25.4 RECENT DEVELOPMENT/NEWS 215
14.26 PFIZER INC. 216
14.26.1 COMPANY SNAPSHOT 216
14.26.2 REVENUE ANALYSIS 216
14.26.3 PRODUCT PORTFOLIO 217
14.26.4 RECENT DEVELOPMENT 217
14.27 RAKSHIT DRUGS PVT. LTD 218
14.27.1 COMPANY SNAPSHOT 218
14.27.2 PRODUCT PORTFOLIO 218
14.27.3 RECENT DEVELOPMENT 219
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD. 220
14.28.1 COMPANY SNAPSHOT 220
14.28.2 REVENUE ANALYSIS 220
14.28.3 PRODUCT PORTFOLIO 221
14.28.4 RECENT DEVELOPMENT 221
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD 222
14.29.1 COMPANY SNAPSHOT 222
14.29.2 REVENUE ANALYSIS 222
14.29.3 PRODUCT PORTFOLIO 223
14.29.4 RECENT DEVELOPMENT 223
14.30 ZYDUS GROUP 225
14.30.1 COMPANY SNAPSHOT 225
14.30.2 REVENUE ANALYSIS 225
14.30.3 PRODUCT PORTFOLIO 226
14.30.4 RECENT DEVELOPMENT 227
15 QUESTIONNAIRE 228
16 RELATED REPORTS 231
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security